| Technical Name |
Glycan-maskingglycan-unmasking hemagglutinin antigens for universal influenza vaccine development |
| Operator |
National Tsing Hua University |
| Booth |
Bio-tech & New Drugs |
| Technical Description |
The invention provides a glycan-masking and/or glycan-unmasking hemagglutinin, wherein the glycosylation site(s) is added on globular headremoved on stem. The glycan-masking and/or glycan-unmasking hemagglutinin may induce neutralizing antibody against influenza virus,cross-reactive protection against different virus. The invention also provides a method for manufacturing these antigens. |
| Scientific Breakthrough |
The invention provides a glycan-masking and/or glycan-unmasking hemagglutinin, wherein the glycosylation site(s) is added on globular headremoved on stem. The glycan-masking and/or glycan-unmasking hemagglutinin may induce neutralizing antibody against influenza virus,cross-reactive protection against different virus. The invention also provides a method for manufacturing these antigens. |
| Industrial Applicability |
The market for seasonal influenza vaccines, sized at US$2.8 billion in 2008–2009 across the major markets, not including the potential of pandemic vaccines. The annual rate of influenza vaccine is approximately 12.6. Our invention provides a glycan-masking and/or glycan-unmasking hemagglutinin antigen design, which can be further used for developing “universal influenza vaccines\". |
| Contact |
陳廷軒 |
